Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study
Autoři:
Lars Christian Lund aff001; Kasper Bruun Kristensen aff001; Mette Reilev aff001; Steffen Christensen aff002; Reimar Wernich Thomsen aff003; Christian Fynbo Christiansen aff003; Henrik Støvring aff001; Nanna Borup Johansen aff005; Nikolai Constantin Brun aff005; Jesper Hallas aff001; Anton Pottegård aff001
Působiště autorů:
Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark
aff001; Department of Anaesthesia and Intensive Care Medicine, Aarhus University Hospital, Aarhus, Denmark
aff002; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
aff003; Biostatistics, Department of Public Health, Aarhus University, Aarhus, Denmark
aff004; Department of Medical Evaluation and Biostatistics, Danish Medicines Agency, Copenhagen, Denmark
aff005
Vyšlo v časopise:
Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med 17(9): e32767. doi:10.1371/journal.pmed.1003308
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pmed.1003308
Souhrn
Background
Concerns over the safety of non-steroidal anti-inflammatory drug (NSAID) use during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been raised. We studied whether use of NSAIDs was associated with adverse outcomes and mortality during SARS-CoV-2 infection.
Methods and findings
We conducted a population-based cohort study using Danish administrative and health registries. We included individuals who tested positive for SARS-CoV-2 during the period 27 February 2020 to 29 April 2020. NSAID users (defined as individuals having filled a prescription for NSAIDs up to 30 days before the SARS-CoV-2 test) were matched to up to 4 non-users on calendar week of the test date and propensity scores based on age, sex, relevant comorbidities, and use of selected prescription drugs. The main outcome was 30-day mortality, and NSAID users were compared to non-users using risk ratios (RRs) and risk differences (RDs). Secondary outcomes included hospitalization, intensive care unit (ICU) admission, mechanical ventilation, and acute renal replacement therapy. A total of 9,236 SARS-CoV-2 PCR-positive individuals were eligible for inclusion. The median age in the study cohort was 50 years, and 58% were female. Of these, 248 (2.7%) had filled a prescription for NSAIDs, and 535 (5.8%) died within 30 days. In the matched analyses, treatment with NSAIDs was not associated with 30-day mortality (RR 1.02, 95% CI 0.57 to 1.82, p = 0.95; RD 0.1%, 95% CI −3.5% to 3.7%, p = 0.95), risk of hospitalization (RR 1.16, 95% CI 0.87 to 1.53, p = 0.31; RD 3.3%, 95% CI −3.4% to 10%, p = 0.33), ICU admission (RR 1.04, 95% CI 0.54 to 2.02, p = 0.90; RD 0.2%, 95% CI −3.0% to 3.4%, p = 0.90), mechanical ventilation (RR 1.14, 95% CI 0.56 to 2.30, p = 0.72; RD 0.5%, 95% CI −2.5% to 3.6%, p = 0.73), or renal replacement therapy (RR 0.86, 95% CI 0.24 to 3.09, p = 0.81; RD −0.2%, 95% CI −2.0% to 1.6%, p = 0.81). The main limitations of the study are possible exposure misclassification, as not all individuals who fill an NSAID prescription use the drug continuously, and possible residual confounding by indication, as NSAIDs may generally be prescribed to healthier individuals due to their side effects, but on the other hand may also be prescribed for early symptoms of severe COVID-19.
Conclusions
Use of NSAIDs was not associated with 30-day mortality, hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy in Danish individuals who tested positive for SARS-CoV-2.
Trial registration
The European Union electronic Register of Post-Authorisation Studies EUPAS34734
Klíčová slova:
COVID 19 – Danish people – Intensive care units – Medical risk factors – NSAIDs – Renal analysis – SARS CoV 2 – Virus testing
Zdroje
1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21. doi: 10.1016/S2213-2600(20)30116-8 32171062
2. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086. doi: 10.1136/bmj.m1086 32184201
3. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. EMA/136850/2020. Amsterdam: European Medicines Agency; 2020 [cited 2020 Aug 3]. Available from: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19.
4. Basille D, Thomsen RW, Madsen M, Duhaut P, Andrejak C, Jounieaux V, et al. Nonsteroidal antiinflammatory drug use and clinical outcomes of community-acquired pneumonia. Am J Respir Crit Care Med. 2018;198:128–31. doi: 10.1164/rccm.201802-0229LE 29461860
5. Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M. Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med. 2019;8:786. doi: 10.3390/jcm8060786 31163625
6. Meganathan P, Awasthi S. Predicting complicated parapneumonic effusion in community acquired pneumonia: hospital based case-control study. Indian J Pediatr. 2019;86:140–7. doi: 10.1007/s12098-018-2769-y 30182278
7. Messika J, Sztrymf B, Bertrand F, Billard-Pomares T, Barnaud G, Branger C, et al. Risks of nonsteroidal antiinflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients. J Crit Care. 2014;29:733–8. doi: 10.1016/j.jcrc.2014.05.021 24997726
8. Epperly H, Vaughn FL, Mosholder AD, Maloney EM, Rubinson L. Nonsteroidal anti-inflammatory drug and aspirin use, and mortality among critically ill pandemic H1N1 influenza patients: an exploratory analysis. Jpn J Infect Dis. 2016;69:248–51. doi: 10.7883/yoken.JJID.2014.577 26255728
9. Lund LC, Reilev M, Hallas J, Kristensen KB, Thomsen RW, Christiansen CF, et al. Association of nonsteroidal anti-inflammatory drug use and adverse outcomes among patients hospitalized with influenza. JAMA Netw Open. 2020;3:e2013880. doi: 10.1001/jamanetworkopen.2020.13880 32609352
10. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Use of non-steroidal anti-inflammatory drugs and clinical outcome of COVID-19: a Danish nationwide cohort study. EUPAS34734. Amsterdam: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance; 2020 [cited 2020 Aug 3]. Available from: http://www.encepp.eu/encepp/viewResource.htm?id=34735.
11. Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 2011;39:12–6. doi: 10.1177/1403494811399956 21898916
12. Pottegård A, Kristensen KB, Reilev M, Lund LC, Ernst MT, Hallas J, et al. Existing data sources in clinical epidemiology: the Danish COVID-19 cohort. Clin Epidemiol. In press.
13. Voldstedlund M, Haarh M, Mølbak K, MiBa Board of Representatives. The Danish Microbiology Database (MiBa) 2010 to 2013. Euro Surveill. 2014;19:20667. doi: 10.2807/1560-7917.es2014.19.1.20667 24434175
14. Schmidt M, Schmidt SAJ, Adelborg K, Sundbøll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–91. doi: 10.2147/CLEP.S179083 31372058
15. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798–798f. doi: 10.1093/ije/dyw213 27789670
16. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90. doi: 10.2147/CLEP.S91125 26604824
17. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39:26–9. doi: 10.1177/1403494811399958 21775346
18. Blichert-Hansen L, Nielsson MS, Nielsen RB, Christiansen CF, Nørgaard M. Validity of the coding for intensive care admission, mechanical ventilation, and acute dialysis in the Danish National Patient Registry: a short report. Clin Epidemiol. 2013;5:9–12. doi: 10.2147/CLEP.S37763 23359787
19. Schmidt M, Hallas J, Friis S. Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999–2012. Clin Epidemiol. 2014;6:155–68. doi: 10.2147/CLEP.S59156 24872722
20. Schmidt M, Hallas J, Laursen M, Friis S. Data resource profile: Danish online drug use statistics (MEDSTAT). Int J Epidemiol. 2016;45:1401–1402g. doi: 10.1093/ije/dyw116 27892409
21. Kristensen KB, Karlstad Ø, Martikainen JE, Pottegård A, Wastesson JW, Zoega H, et al. Nonaspirin nonsteroidal antiinflammatory drug use in the Nordic countries from a cardiovascular risk perspective, 2000–2016: a drug utilization study. Pharmacotherapy. 2019;39:150–60. doi: 10.1002/phar.2217 30636337
22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55. doi: 10.1093/biomet/70.1.41
23. Sturmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study. Am J Epidemiol. 2010;172:843–54. doi: 10.1093/aje/kwq198 20716704
24. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Boston: Boston College Department of Economics; 2018 [cited 2020 Aug 3]. Available from: https://ideas.repec.org/c/boc/bocode/s432001.html.
25. Pottegård A, Kurz X, Moore N, Christiansen CF, Klungel O. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. Pharmacoepidemiol Drug Saf. 2020 May 5. doi: 10.1002/pds.5029 32369865
26. Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. Metrics for covariate balance in cohort studies of causal effects: metrics for covariate balance in cohort studies of causal effects. Stat Med. 2014;33:1685–99. doi: 10.1002/sim.6058 24323618
27. Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012;21:697–709. doi: 10.1002/pds.2256 22162077
28. Gribsholt SB, Pedersen L, Richelsen B, Thomsen RW. Validity of ICD-10 diagnoses of overweight and obesity in Danish hospitals. Clin Epidemiol. 2019;11:845–54. doi: 10.2147/CLEP.S214909 31572015
29. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiol. 2001;12:682–9. doi: 10.1097/00001648-200111000-00017 11679797
30. Schmidt M, Lamberts M, Olsen A-MS, Fosbøll E, Niessner A, Tamargo J, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2016;2:108–18. doi: 10.1093/ehjcvp/pvv054 27533522
31. Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131:97–106. doi: 10.1159/000375362 25896805
32. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 May 5. doi: 10.1001/jamacardio.2020.1855 32369097
33. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431–40. doi: 10.1056/NEJMoa2006923 32356627
34. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441–8. doi: 10.1056/NEJMoa2008975 32356628
Článek vyšel v časopise
PLOS Medicine
2020 Číslo 9
- S diagnostikou Parkinsonovy nemoci může nově pomoci AI nástroj pro hodnocení mrkacího reflexu
- Proč při poslechu některé muziky prostě musíme tančit?
- Chůze do schodů pomáhá prodloužit život a vyhnout se srdečním chorobám
- „Jednohubky“ z klinického výzkumu – 2024/44
- Je libo čepici místo mozkového implantátu?
Nejčtenější v tomto čísle
- Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
- COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
- Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis
- Long-term survival of children born with congenital anomalies: A systematic review and meta-analysis of population-based studies
